Hearts That Heal Can Let Go of the Pills

Key Takeaway: The HER-SAFE trial, the first randomized controlled study of its kind, has demonstrated that breast cancer patients whose heart function has fully recovered from treatment-induced cardiotoxicity can safely discontinue their heart failure medications. During a twelve-month follow-up, cessation of therapy did not lead to a significant decline in cardiac function, cardiovascular death, or hospitalization for heart failure. This result paves the way for evidence-based de-prescribing in this expanding patient population.

A Lingering Question in Cardio-Oncology

Imagine you have completed your life-altering battle against breast cancer. The chemotherapy worked. The targeted therapy did its job. But along the way, your heart took a hit; its pumping function weakened, and you were started on heart failure medications to protect the heart muscle. Months later, your heart has recovered. Your imaging results are normal. You feel well. Yet every morning, you continue to swallow pills prescribed for a problem that no longer exists. For how long? Forever? Until now, no one could provide a definitive answer. The HER-SAFE study finally delivers one.

The Clinical Dilemma: The Challenge of De-Prescribing

Anti-HER2 therapies like trastuzumab have revolutionized the treatment of HER2-positive breast cancer, dramatically improving survival^[2]. However, these drugs can cause cancer therapy-related cardiac dysfunction (CTRCD), which is defined as a drop in the left ventricular ejection fraction (LVEF)—a measure of how effectively the heart pumps blood with each beat. A normal LVEF is around 55-70%. When a significant drop occurs during treatment, clinicians typically initiate heart failure therapy (HFT), which includes a combination of ACE inhibitors or ARBs and beta-blockers. These are the same medications used in traditional heart failure treatment^[3].

But there is a crucial distinction: Trastuzumab-related cardiac dysfunction is fundamentally different from the permanent damage caused by older chemotherapy agents like doxorubicin. Anthracyclines destroy heart muscle cells through oxidative stress and direct mitochondrial damage, often leading to irreversible scar tissue^[4]. In contrast, trastuzumab interferes with the HER2 signaling pathway, which is essential for cellular stress response and repair in cardiac cells, but it typically does so without causing structural damage. When the drug is discontinued, this dysfunction is often reversible^[5]. This distinction is critical: If the heart recovers, does it still need the medications that got it there? For years, clinicians have had to rely on educated guesses. The HER-SAFE study has now replaced that guesswork with data.

What Did the Researchers Do?

The HER-SAFE trial, a randomized controlled study—the gold standard of clinical evidence—enrolled 90 breast cancer patients who had experienced CTRCD during anti-HER2 therapy and whose heart function had subsequently returned to normal. Patients were randomly assigned to one of two groups: 45 patients discontinued their heart failure medications, while 44 continued them. The primary endpoint was whether patients experienced a moderate or severe decline in their heart function over a 12-month follow-up period^[1].

The Findings

The results were remarkably reassuring. In the group that stopped the medications, only 1 out of 45 patients experienced a significant drop in heart function. In the group that continued the drugs, none of the 44 patients saw such a decline. The difference between the groups was just 2.2%—a margin so small that it did not suggest any meaningful additional risk from discontinuing therapy. Perhaps most importantly, there were no cardiovascular deaths, hospitalizations for heart failure, or symptomatic cardiac events in either group. LVEF remained stable in both arms at the 12-month follow-up.

In simpler terms: The recovered hearts stayed recovered, whether the medications were continued or not.

The Mechanism: Why Is the Recovery Durable?

Understanding why these results are biologically plausible requires a closer look at how trastuzumab affects the heart. The HER2 receptor is not just a cancer target; it also plays a vital role in the survival of cardiac myocytes, especially under conditions of hemodynamic stress. When trastuzumab blocks this receptor, the heart temporarily loses a key protective signal, and its contractile function can weaken. However, unlike the necrosis and fibrosis caused by anthracyclines, trastuzumab-related dysfunction involves reversible changes in cellular energy metabolism and sarcomere organization rather than permanent cell death^[5]. Once the drug is cleared from the body and the HER2 pathway is reactivated, the myocardium can fully regain its contractile strength.

This is analogous to a muscle weakening from disuse but regaining full function with rehabilitation; the underlying architecture remains intact. Heart failure drugs like beta-blockers and ACE inhibitors support the heart during this vulnerable period by reducing afterload and neurohormonal activation^[3]. But once the underlying insult is removed and recovery is complete, the rationale for continuing these medications often disappears.

What These Findings Mean for Patients

For the growing population of breast cancer survivors living with the burden of polypharmacy, the HER-SAFE trial offers tangible relief. These medications are not without side effects; fatigue, dizziness, low blood pressure, and sexual dysfunction are commonly reported with beta-blockers and ACE inhibitors. There is also their cost and the psychological weight of a daily reminder of illness. For patients with proven recovery of cardiac function, being able to safely discontinue these drugs represents a significant improvement in quality of life.

This study also signals a broader shift in cardio-oncology: a move away from a one-size-fits-all approach toward a more nuanced, personalized strategy. Not every patient who experiences cardiac dysfunction during cancer treatment needs to be on heart medication for life. The key is careful patient selection; this study enrolled patients whose LVEF had fully normalized, and they were monitored closely throughout the process.

Important Limitations

The HER-SAFE study included 90 patients; while a meaningful number for a first-of-its-kind trial, it is still modest. The follow-up period was 12 months; whether this safety extends to five or ten years remains unknown. The study also focused specifically on anti-HER2 therapy-related dysfunction, meaning the findings should not be generalized to patients whose heart damage was caused by anthracyclines or other cardiotoxic agents. Most importantly, the patients enrolled had fully recovered heart function; these results are not a green light for those with a persistently low LVEF to stop their medications. Larger and longer-term studies will be needed to confirm and expand upon these findings in broader populations.

Scientific Sources

1. Dowsing B, et al. Safety of withdrawal of pharmacological treatment after recovery from HER2 therapy-related cardiac dysfunction: the HER-SAFE trial. European heart journal. 2026. PubMed: https://pubmed.ncbi.nlm.nih.gov/42669033/
2. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001. DOI: 10.1056/NEJM200103153441101
3. McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021. DOI: 10.1093/eurheartj/ehab368
4. Cardinale D, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015. DOI: 10.1161/CIRCULATIONAHA.114.013777
5. Ewer MS, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005. DOI: 10.1200/JCO.2005.13.300